Table 1.
Demographic and Clinical Characteristics of Patients at Baseline
| Variable | Patients receiving ddI/3TC/EFV (n = 104) | Patients receiving ddI/3TC/NVP (n = 64) | P |
| Age, years | 35 (6.9) | 37 (7.7) | .06 |
| Weight, kg | 41.9 (7.9) | 42.0 (7.7) | .89 |
| Male sex, no. (%) of patients | 81 (78) | 51 (80) | .78 |
| Alcohol habituated, no. (%) of patients | 43 (41) | 31 (48) | .14 |
| CD4+ cell count, median cells/mm3 (IQR) | 90 (53–130) | 75 (34–130) | .14 |
| Viral load, median copies/mL (IQR) | 259000 (81200–531000) | 203000 (87900–370000) | .79 |
| Triglycerides level, median mg/dL (IQR) | 123 (96–164) | 113 (92–173) | .74 |
| HDL-cholesterol level, median mg/dL (IQR) | 26 (20–32) | 24 (20–32) | .66 |
| Total cholesterol level, mg/dL | 124 (34) | 126 (32.6) | .65 |
| LDL-c level, mg/dL | 82 (26) | 79 (25.9) | .49 |
| Fasting glucose level, mg/dL | 97 (26) | 91 (13) | .11 |
NOTE. Data are mean values (± standard deviation) unless otherwise indicated. For comparison between groups, the Student’s t test was used for mean values and the Wilcoxon rank-sum test was used for median values. 3TC, lamivudine; ddI, didanosine; EFV, efavirenz; HDL-c, high-density lipoprotein cholesterol; IQR, interquartile range; LDL-c, low-density lipoprotein cholesterol; NPV, nevirapine.